申请人:Controlled Chemicals, Inc.
公开号:EP1782834A2
公开(公告)日:2007-05-09
The abuse potential of a bioavailable drug such as an opiate analgesic agent is reduced and its duration of action is extended by converting it to a poorly absorbed ester prodrug derivative prior to formulation. Unlike many existing sustained release formulations of active pharmaceutical agents wherein an active pharmaceutical agent can be released by chewing, crushing or otherwise breaking tablets or capsule beads containing the active pharmaceutical agent, such mechanical processing of tablets or capsule beads containing a prodrug of this invention neither releases the active drug nor compromises the controlled conversion of prodrug to drug. Moreover, tablets and capsule beads containing prodrugs of this invention or other drugs can be formulated with a sufficient amount of a thickening agent such as hydroxypropylmethylcellulose to impede inappropriate intravenous and nasal administration of formulations that are not indicated for these modes of administration.
通过在配制前将生物可利用药物(如阿片类镇痛剂)转化为吸收性较差的酯类原药衍生物,可降低其滥用可能性并延长其作用时间。与许多现有的活性药剂缓释制剂不同,含有本发明原药的片剂或胶囊珠通过咀嚼、碾碎或其他方式破碎,活性药剂就会释放出来,而对含有本发明原药的片剂或胶囊珠进行这种机械加工,既不会释放出活性药物,也不会影响原药向药物的可控转化。此外,含有本发明原药或其他药物的片剂和胶囊珠剂可以配制足量的增稠剂,如羟丙基甲基纤维素,以防止不适合静脉注射和鼻腔给药的制剂,因为这些制剂并不适用于这些给药方式。